Table 1 Clinical inputs into the model and sources of information

0.823

Olivares [26]

0.872

RIS rate adjusted via Mehnert [27]

0.763

Calculation [1 - (ER exacerbation rate + hospitalization rate)]

0.803

Calculation [1 - (ER exacerbation rate + hospitalization rate)]

0.071

Ratio of ER vists: hospitalizations Ascher-Svanum [28]

0.059

Ratio of ER vists: hospitalizations Ascher-Svanum [28]

0.166

Olivares [29]

0.138

Gopal [14], Hough [13]

0.140

Kane [30]

0.148

Hough [13]

0.274

Calculation [1 - (Stable rate + hospitalization rate)]

0.299

Calculation [1 - (Stable rate + hospitalization rate)]

0.586

Assumption; PP rate adjusted based on calculations by Mehnert & Diels [27]

0.553

Morken [31]

40.3 mg biweekly

Fleischhacker [15], Kissling [32], Lee [33], Lindenmayer [34], Olivares [29]

69.3 mg monthly

Gopal[14], Fleischhacker [15]

50 mg biweekly*

Risperdal Consta® Approved Summary of Product Characteristics [10] maximum dose

84.9 mg monthly

Gopal [35], Pandina [36], Hough [16], Nasrallah [37], Pandina [38]

50 mg biweekly*

Risperdal Consta® Approved Summary of Product Characteristics [10] maximum dose

150 mg week 1, 100 mg week 2, then 84.9 mg every 4 weeks

Xeplion® Product monograph [12], Hough [13]

450 mg daily

Simonsen[23], Wahlbeck [24]

750 mg daily

Simonsen[23], Wahlbeck [24]